Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Jean-Jacques Bienaimé
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusArea |
gptkb:phenylketonuria_(PKU)
gptkb:hemophilia_A genetic disorders mucopolysaccharidosis enzyme replacement therapies CLN2 disease |
| gptkbp:founded |
1997
|
| gptkbp:founder |
Christopher Starr
Grant W. Denison Jr. |
| gptkbp:headquarters_location |
gptkb:San_Rafael,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
BioMarin Pharmaceutical
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:member |
gptkb:S&P_500
gptkb:NASDAQ_Biotechnology_Index |
| gptkbp:notableProduct |
gptkb:Aldurazyme
Brineura Kuvan Naglazyme Palynziq Roctavian Vimizim |
| gptkbp:numberOfEmployees |
over 3,000
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
orphan drugs
rare diseases |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
BMRN
|
| gptkbp:website |
https://www.biomarin.com/
|
| gptkbp:bfsParent |
gptkb:PhRMA
|
| gptkbp:bfsLayer |
6
|